How One Postdoctoral Fellowship Award Recipient Is Helping to Expand Our Knowledge of the Fundamental Mechanisms of Neurodegenerative Diseases

Kristen Whitney, PhD, and John F. Crary, MD, PhD, in the Crary Lab

Kristen Whitney, PhD, whose research in the Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, is aimed at uncovering the earliest changes that occur in the aging brain that are causing cells to die, was named the 2024 recipient of the Robin Chemers Neustein Postdoctoral Fellowship Award.

The award, which encourages and supports female research scientists at Icahn Mount Sinai, was established in 2010 through a generous gift from Robin Chemers Neustein, JD, MBA, a former member of Mount Sinai’s Boards of Trustees. Recipients are senior postdoctoral scientists who intend to complete their training within two years, have demonstrated high-impact accomplishments in biomedical sciences, and exhibit the potential for an independent scientific career.

Dr. Whitney is a postdoctoral fellow in the John F. Crary, MD, PhD, Lab. Dr. Crary is Director of the Mount Sinai Neuropathology Brain Bank and Research CoRE, and Professor of Pathology, Molecular and Cell-Based Medicine, Artificial Intelligence and Human Health, and Neuroscience, Icahn Mount Sinai. His lab is dedicated to uncovering the fundamental mechanisms of neurodegenerative diseases with a focus on the tau protein, the principal component of neurofibrillary tangles seen in Alzheimer’s disease and other disorders, such as progressive supranuclear palsy (PSP).

Says Dr. Crary: “Dr. Whitney is at the forefront of this effort, spearheading innovative research that uses stem cell-derived brain organoids to model PSP. Her work is specifically focused on understanding the role of the integrated stress response in tauopathy, helping to illuminate how cellular stress pathways influence the progression of tau-related diseases. Her contributions are critical in advancing our understanding of PSP, positioning her as a leader in neurodegenerative disease modeling.”

Understanding these mechanisms is a promising path to identifying novel therapeutic strategies and drug targets to delay or cure these devastating diseases.

Dr. Whitney says she first became interested in neurodegenerative diseases in her freshman year of college when she started working as a histology technician in a neuropathology lab. Later, she worked directly with patients as a clinical research coordinator at an Alzheimer’s Disease Research Center. “I observed firsthand the devastating consequences of these diseases,” she says.

In her doctoral work, she investigated a novel drug therapy for traumatic brain injury in preclinical animal models. “My training background in both clinical and basic science research, and working with human samples and model systems, inspired the direction of my postdoctoral work in experimental neuropathology and human patient-derived brain cell model systems,” she says.

“I feel the most powerful way to identify therapeutic strategies for neurodegenerative diseases is to conduct patient-oriented research, focusing on the precious brain donations from our patient populations and developing new personalized, and thus clinically relevant-based model systems, such as our ‘mini-brain’ organoids.”

Dr. Whitney came to Mount Sinai for postdoctoral training specifically to work with Dr. Crary. “His background as a physician-scientist offered a unique opportunity to learn clinical and experimental neuropathology while conducting translational research,” she says.

“Mount Sinai has been an incredible environment to complete my postdoctoral training, particularly in the stem cell, organoid, and neurodegenerative research community,” Dr. Whitney adds. “I have had the opportunity to be mentored by, and collaborate with, some of the top researchers in the field. My projects would never have been possible without all the resources available at Mount Sinai, especially the Dean’s CoREs, such as the Stem Cell Engineering CoRE and the Mount Sinai Neuropathology Brain Bank and Research CoRE.”

“I am beyond thrilled and honored to be selected for this year’s Robin Chemers Neustein Postdoctoral Fellowship Award,” says Dr. Whitney. “Advocacy for women in science and the commitment to dismantling barriers resonate deeply with my values, making the mission of this award especially meaningful for me. I am so grateful to Dr. Crary for his invaluable mentorship throughout the years, and to the selection committee for their recognition and support.”

Mount Sinai Team Presents Research at World Professional Association for Transgender Health 28th Scientific Symposium

The Mount Sinai team at the World Professional Association for Transgender Health 28th Scientific Symposium in Lisbon, Portugal.

At the recent World Professional Association for Transgender Health (WPATH) 28th Scientific Symposium, “A Gender Diverse World in Global Unity,” Joshua Safer, MD, FACP, FACE, Executive Director of the Mount Sinai Center for Transgender Medicine and Surgery, and others from Mount Sinai presented leading-edge research on hormone therapy for transgender and gender-diverse patients.

This presentation was one of 17 delivered by the Mount Sinai team, showcasing their commitment to advancing knowledge and promoting access, equity, and inclusion in health care.

The symposium, held from September 25-30 in Lisbon, Portugal, brought together medical experts, advocates, students, and colleagues from around the world to share insights and collaborate on advancing transgender and gender-diverse health care.

Mount Sinai’s Center for Transgender Medicine and Surgery, alongside the Office for Diversity and Inclusion, played a key role in the symposium and hosted a reception that allowed participants to network and discuss important research, highlights, and best practices in the field.

Dr. Safer was a panelist in a discussion of adjunct agents, or additional therapies, used with estrogens for feminizing hormone therapy in transgender women. In addition, Daniel J. Slack, MD, Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease), presented important data suggesting that blood clots in transgender women might be connected to other medical conditions and health care access issues rather than the estrogen therapy that is often blamed.

Presentations by the Mount Sinai team also included substantial data regarding the benefits of specific gender-affirming surgical techniques and opportunities to address health care gaps for transgender people.

Together, we are pushing the boundaries of research and championing the health and well-being of all,” Dr. Safer says. “We look forward to continuing this vital work and building a future where everyone can thrive.”

How Did These New York City Teachers Spend Their Summer? In Mount Sinai Labs, Improving Their Science and Teaching Skills

New York City educators visited the Microscopy and Advanced Bioimaging Core facility with Glenn Doherty, Senior Core Research Associate, seated left, and Denise Croote, PhD, seated right.

New York City high school teacher Christine Chan, middle school teacher Elsa Rosario, and assistant principal Kathy Pham gained hands-on experience in science content, communications, and teaching at Mount Sinai as part of a Summer Research Program for Science Teachers. They recently returned to their classrooms energized with fresh ideas to inspire a love of science in their students.

Ms. Chan worked in the laboratory of renowned scientist Yasmin Hurd, PhD, the Ward-Coleman Chair of Translational Neuroscience, Director of the Addiction Institute of Mount Sinai, and Professor of Pharmacological Sciences, Neuroscience, Psychiatry, and Artificial Intelligence and Human Health.

Ms. Rosario worked in the laboratory of researcher Joel Blanchard, PhD, Associate Professor of Neuroscience, and Cell, Developmental and Regenerative Biology, and a core member of Mount Sinai’s Institute for Regenerative Medicine, who is developing in vitro models of the human brain.

Ms. Pham worked in the laboratory of researcher Yizhou Dong, PhD, Professor of Immunology and Immunotherapy, and Oncological Sciences, whose research is focused on drug discovery and delivery.

Mount Sinai was among four institutions hosting teachers through a program that was founded in 1990 by the esteemed scientist Samuel C. Silverstein, MD, at Columbia University.

“This program has created a wonderful community of science educators and researchers who are eager to enhance science education in the United States and prepare the next generation for careers in science, technology, engineering, and math,” says Denise Croote, PhD, Assistant Professor of Neuroscience, and an instructor in the Center for Excellence in Youth Education at Mount Sinai, who oversaw the Mount Sinai program for The Friedman Brain Institute, which hosted the teachers.

Ms. Pham was completing her second year in this two-summer program, while Ms. Chan and Ms. Rosario expect to return next summer and continue building on their first-year experiences in the laboratories.

“We were thrilled to welcome New York City science educators to our labs, and we are excited to work together on outreach programs that support their classroom goals in the upcoming year,” says Dr. Croote.

In addition to their work in the labs, activities for all of the teachers included a small symposium and poster session, and Professional Development Days, where, at Mount Sinai, they presented a science lesson of their choice, learned about resources available to them, and toured the Microscopy and Advanced Bioimaging Core and the BioMedical Engineering and Imaging Institute, interacting with faculty and staff.

“The experience was a perfect blend of collaboration, learning, and the joy of sharing knowledge with those who shape the future of science,” says Natalia P. Biscola, PhD, Associate Scientist in Mount Sinai’s Department of Neurology, who helped organize and develop the summer program at Mount Sinai. Adds Veronica Szarejko, Program Manager, Nash Family Department of Neuroscience, “As a mother of a high school freshman who is a science enthusiast, I am incredibly excited about the program’s ability to promote new ideas and help shape how the science curriculum is taught in New York City schools.”

For Ms. Chan, Ms. Rosario, and Ms. Pham, it was an extraordinary opportunity. Read on to learn more about what they learned and why they are passionate about teaching science.

Christine Chan, in the lab with Alexandra Chisholm, PhD

Christine Chan, ReStart Academy

Can you share a little background on your teaching experience?

I am starting my fourth year as a high school science teacher at District 79’s ReStart Academy at the Comprehensive Adolescent Rehabilitation and Education Service (CARES). I have taught biology, earth and space science, and environmental science. Our school collaborates with Mount Sinai to provide a safe space for students with mental disorders to simultaneously receive public-school education and outpatient psychiatry therapy.

Our student body is more diverse than any other school in the country. We have art school students, specialized high school students, special education students, LGBTQ+ students, and students from other minority groups. Although it can be challenging at times to have such a diverse group of students in the classroom, it does lead to unexpected perspectives and insights. Learning is bidirectional. I can inspire students and help them discover new aspects of themselves, while they introduce me to a broad variety of knowledge.

Who inspired you to become a science teacher?

I enjoyed my college science classes more than my high school science classes. While it was much more challenging, the content was much more relevant to my personal life. I found myself more easily drawn to science learning and asking more questions about the world around me. Science has enlarged my interests in health, scientific innovation, medicine, climate change, and sustainability.

I was inspired to become a science high school teacher because I think the excitement around science learning should be encountered earlier. I want to become a teacher who teaches science in a way that is relevant, rigorous, and fun for young students. I also want to inspire and motivate young people to care more and take action about major societal problems, such as health disparities, climate change, and the lack of diversity in science, technology, engineering, and mathematics fields.

I believe there are creative ways to teach rigorous and exciting science while also preparing students for standardized tests. For example, while we must teach fundamental concepts of the endocrine and reproductive system, why can’t we teach it in the context of our students’ real worlds? They are more likely to pay attention, care, and invest time in learning. Many of my students are transgender, so they have heard of or may be taking testosterone or estrogen shots. I can teach students fundamental biology and help them apply conceptual knowledge to understand real applications of medicine.

What did you learn through the activities, and especially working in the lab with a mentor?

My experience in the Hurd lab taught me that science and technology are advancing simultaneously. In the past, I was under the impression that people learn to code and program because they want to work in IT or make cool computer programs. As technology opens the door to large amounts of complex data, scientists need coding skills to use programs that can comprehend the information. Researchers in the Hurd lab write codes to make sense of and analyze large amounts of data from RNA sequencing. Scientists need to be flexible and lifelong learners to keep up with the latest programs and research methods.

In addition, I learned that a strong background in the biological mechanism of a research topic is essential. Without a fundamental background understanding, it is very hard to conduct literature searches, stay updated within the scientific community, understand methodology and results, and draw conclusions. Overall, the results of research projects are often very complex because the brain is very complex. There is still so much we don’t know about the brain.

What lessons will you take to the classroom?

My experience in the Hurd Lab, guidance from my lab mentor, Alexandra Chisholm, PhD, and professional development sessions have all inspired me. I plan to use some physical, interactive models acquired in my professional development sessions, to teach synapses. For example, I can have students throw balls (neurotransmitters) from the presynaptic neuron into the receptors (cups) of postsynaptic neurons. I can use this model to teach about neural communication and neuroplasticity.

I also want to encourage my students to learn coding via datacamp.com. I was enrolled in some courses during my time in the Hurd lab, where I acquired a great set of introductory skills. Educators can help students enroll in six-month coding courses that are interactive and project based. This is a great fit for my school because we don’t have a computer science teacher.

The Hurd lab also inspired me to create a bioinformatic poster project. Dr. Hurd is actively working to bridge the connection between the research community and the larger society, and she teaches her college interns the importance of this connection by assigning them a bioinformatics poster about prenatal exposure to cannabis. I think students can solidify their understanding of any topic by making posters to inform or educate local communities. For example, my students are very passionate about LGBTQ+ activism. I plan to have them create bioinformatic posters for trans teens about the mechanisms behind hormone replacement therapy.

Lastly, I plan to utilize some of the connections I built during this experience to coordinate field trips to science research labs or facilities to give students a better sense of where scientists work, what problems researchers are investigating

Elsa Rosario in the lab with Andrea Perez Arevalo, PhD

Elsa Rosario, Rachel Carson I.S. 237

Can you share a little background on your teaching experience?

I have been a middle school teacher for five years at Rachel Carson I.S. 237 in Flushing, Queens, New York. I teach sixth and seventh grade science, as well as Living Environment and Earth Science Regents Prep to eighth graders.

While middle school students have acquired a lot of skills by the time they get to me, they are still full of curiosity for the world around them. They are ready to identify problems and try to find solutions and get an allocated time for science every day in school. I also think it is the perfect time to get them interested in science through experiences, such as using scientific hands-on models to learn and answer questions. Experiences stay with us and help shape who we become.

Who inspired you to become a science teacher?

I attribute a lot of what I have accomplished to the educators who mentored and believed in me through different stages of my education career. Growing up, I never envisioned becoming a teacher, much less a science teacher. I wasn’t born in the United States, and in the country I am from, languages and math were the main subjects we focused on in middle school.

After I moved to New York City as a teenager I first got interested in science because of my Living Environment teacher talking so passionately about genetics and all the different possibilities researching genetics could lead to. This experience led me to college and a major in Biotechnology. I got the opportunity to do research as an undergraduate student, and my mentors at the time supported me to become a lab instructor, an experience that changed everything for me. It made me realize that sharing knowledge and empowering others to see the world in a critical way could impact more lives. We make choices every day, and the skills you learn in science class are very transferable to your everyday life. We just fail to see it through that lens sometimes.

What did you learn through the activities, and especially working in the lab with a mentor?

I truly believe no book or diagram can help you make a connection with something the way an experience can. I have gained an appreciation for the brain that no class in neuroscience could have ever taught me.

I have used all my senses to fully immerse myself into understanding the brain in this internship. Andrea Perez Arevalo, PhD, my mentor in the Blanchard lab, guided me through identifying a question of interest after doing research, carrying out hands-on qualitative and quantitative experiments to answer that question, and analyzing the result to make conclusions.

And, something else. I have also become a student again and that can really change your perspective, especially when you are being introduced to an unfamiliar topic. It’s the kind of feeling my students have when I stand in front of the class to teach. The internship was also a one-to-one experience, and my mentor addressed any misconceptions I might have had as I learned. That gave me a better understanding of how everything I was learning connected to my everyday life —and how I might use this experience to better teach my students how molecular interactions impact the way their brains work.

What lessons will you take to the classroom? 

One of the most important lessons I have learned from my mentor is that failure can also be a story of success in life and science! When you try something, and you fail, then you have learned what does not work. What matters is what you do with that knowledge.

Some of the experiments we completed did not give us the results we expected, and my mentor made sure we focused on taking that data for what it was and still analyzed what it meant. It is okay to have expectations when you do an experiment, that is what a hypothesis is, but focusing on that might narrow your field of view when analyzing your results. Not doing this might make us miss an opportunity to understand the process we are investigating.

I was also given the opportunity to create my own microscope slides with different types of brain cells that had different pathology. I plan to create a lab in which students collect data from these slides about how cells change in the brain when someone has a neurodegenerative disorder.

Kathy Pham giving a presentation

Kathy Pham, Bard High School Early College, Queens

Can you share a little background on your teaching experience?

I have been teaching for 12 years, primarily in Title I, low-income, and underperforming schools in the East New York and Bushwick sections of Brooklyn, where I focus on biology for grades 9 to 12. It has been a rewarding journey that allows me to engage with students and cultivate their curiosity in science. Many of my students continue to pursue their studies in the sciences as they advance to higher education.

Who inspired you to become a science teacher?

My inspiration originated from my seventh-grade science teacher who instilled in me a profound love for inquiry and discovery. We participated in science fairs, competed in science competitions, and conducted scientific research. The passion she exhibited for science was contagious, and I strive to ignite that same enthusiasm in my students.

What did you learn through the activities, and especially working in the lab with a mentor?

Working in the lab with a mentor has been incredibly beneficial. I have gained hands-on experience in the formulation of lipid nanoparticles using polysarcosine for mRNA delivery therapeutics, which has deepened my understanding of immunology and cellular biology. Additionally, this experience has underscored the importance of experimentation and critical thinking in science, reinforcing the necessity of fostering a similar environment in the classroom.

What lessons will you take to the classroom? 

I plan to create lessons that prioritize inquiry-based learning and collaborative projects. I believe that by emphasizing active learning and experimentation, I can cultivate a more dynamic and engaging atmosphere for my students.

Spotlight on Nursing Research: Addressing Knowledge Gaps in Sickle Cell Disease Pain Treatment

Charleen Jacobs-McFarlane, PhD, RN, ANP-BC

The Center for Nursing Research and Innovation at Mount Sinai recently interviewed Charleen Jacobs-McFarlane, PhD, RN, ANP-BC, a Nurse Practitioner in the Mount Sinai Health System Adult Sickle Cell Program, who has published abstracts in Practical Implementation of Nursing Science focused on the knowledge gaps in sickle cell disease pain treatment and on the factors influencing the decision to seek curative treatment.

What drew you to sickle cell disease research earlier in your career, and what sustains your interest today?

I was drawn to sickle cell disease (SCD) research by coincidence when I had my first NP clinical rotation at Mount Sinai’s Sickle Cell Program as a student nurse practitioner. At that time it was a much smaller program, but there were some research projects going on that sparked my interest. While taking care of people with SCD there were many different phenomena that were occurring simultaneously—in particular, the physiological manifestations of the disease, the complex care management involved, and most importantly, the patient’s experience living with a chronic illness. I thought it would be best to enroll in a PhD in nursing program to gain skills as a nurse researcher and to be better equipped to pursue the unanswered questions I encountered.

Can you give an example?

A small number of the patients I cared for received a bone marrow transplant to cure the disease and alleviate one of the most prominent features of SCD—pain. However, while these patients were technically cured, some continued to have pain. They expressed to me that they felt lost and disconnected from the SCD community because they did not have SCD anymore, and they wondered if they made the right choice in curing their disease because of their continued pain. My dissertation focused on the experience of deciding to pursue curative therapies in SCD. I believe the findings of that study could help us clinicians understand how patients move through making such a life-changing decision and how we can be better equipped to guide them through that experience, and determine what resources are needed to support them along the journey. The patients are what continue to sustain my interest today, because there are so many unanswered questions and gaps in SCD research that need to be addressed. People with SCD continue to have poor outcomes compared to others. I believe that through continued research, we can improve the lives of people with SCD.

In your experience, how has your clinical work been informed by pursuing a PhD, and vice versa?

The longer I practice, the more I refine my research. And since my research in SCD focuses on specific clinical problems and nursing practice within this space, the direct application of my research informs my clinical practice. Pursuing a PhD has sharpened by ability to critically analyze clinical situations, identify underlying patterns and phenomena, and apply evidence-based practice more effectively as a nurse practitioner. My knowledge base in SCD care deepened as I found myself going to the literature more frequently to get answers and to seek clarity with complex cases to ensure that an intervention was grounded in research. Additionally, the rigor of the PhD program inspired me to take on a more analytical mindset while caring for patients, and opened a path for me to generate questions for future research and to imagine how I would approach answering those questions. But while my PhD was research based, there was a heavy focus on leadership and advocacy as well. Using the latest research to inform best practices, influence policy changes, and promote clinical innovation to advance care was of utmost importance, and I continue to make sure I am doing that in my day-to-day practice. Additionally, another clinical influence on my PhD was the opportunity to work with people with SCD, which was a huge advantage. I had experience, insight, and practical perspectives to inform my research. Working directly with patients and various members of the health care team allowed me to identify gaps in current knowledge and where I could focus my research and methodologies.

What strategies have you adopted or developed to balance your clinical and academic pursuits?

It all comes down to time management. I try to stay organized using planners and jotting down my goals for the week. On my clinical days, I am fully immersed in the activities of the sickle cell program. A large majority of my research questions come from clinical practice, and if something of interest comes up clinically, I write it down as a potential project to explore at another time. I have a running list of research questions that are saved in my notes for future reference. On my academic days, I try to focus solely on academic pursuits—no clinical work at all. The questions saved from my clinical days are researched on my academic days. Allocating specific days and times for clinical and academic work has helped me a lot in maintaining structure and reduces the cognitive load of switching between roles. My mentor, Jeffrey Glassberg, MD, advised me on the idea of identifying and prioritizing tasks that are of “critical importance” to achieving my most pressing goals. It has helped me clear a lot of mental clutter, refocus my energy on my research career, and identify parts of my clinical role that can be delegated to others. I started a post-doctoral training program earlier this year and, honestly, I struggled for a few months switching between both worlds. Over time the balance has improved, but it is something on which I am continually working.

How have your research interests been affected by working with an interdisciplinary team at Mount Sinai?

I am fortunate to collaborate with an interdisciplinary team of clinicians who are also National Institutes of Health-funded sickle cell researchers. Their expertise and research achievements are inspiring and bring a culture of high academic and clinical standards to the program. Our interdisciplinary work focuses on delivering high-quality, equitable, patient-centered care for all patients with SCD. The collaboration between physicians, nurse practitioners, nurses, social workers, research staff, and others allows the team to gain invaluable insights from one another on how to best implement our research findings into practice. It creates a feedback loop for our team, and also helps ensure that my own research remains relevant and beneficial to our patients. Research does not get done in silos. Collaboration between team members is essential to advance the research and the care of people living with SCD. Being a nurse practitioner on such a dynamic team has highlighted how crucial this role is, as we often integrate research activities into our clinical work.

Your abstracts published in Practical Implementation of Nursing Science focused on the knowledge gaps in SCD pain treatment and on the factors influencing the decision to seek curative treatments—how did your clinical relationship to your patients help identify these topics, and what advice would you give to other nurses looking to develop a research question?

My advice for nurses looking to develop a research question would be to start with your clinical area of expertise or interesting things that continue to occur in your area. Because SCD is a chronic illness, and we follow patients through the continuum of care (inpatient and outpatient), I have developed long-term relationships with our patients and their families. They not only share their struggles, but also their successes in overcoming adversity while living with SCD. As I follow patients longitudinally, I am acutely aware of the lack of treatment options for chronic SCD pain, and while curative therapies are a hot topic, they remain inaccessible for many people with SCD. In “Descriptive Analysis of Buprenorphine Inductions in Adults with Sickle Cell Disease,” we investigate the small number of our patients with SCD who often have pain, repeated hospitalizations, and a poor response to the standard treatment with opioids who are in need of additional treatment options. Some of those patients were frustrated with the lack of pain control, and the use of buprenorphine to reduce acute care visits was emerging in SCD treatment. We were curious to see the outcomes of acute care visits and opioid use before and after starting buprenorphine at our institution. In “The Lived Experience of Deciding Curative Treatments for Adults With Sickle Cell Disease,” building on discussions about curative therapies with patients with severe cases of SCD, I found that while this population was aware of the severity of their disease, they often expressed feeling overwhelmed by the decision to move forward with curing their disease for a multitude of reasons, and they often had repeated conversations over months, and sometimes years, about being referred to a transplant therapist. There was some existing research on this phenomenon, but little that focused on adults with SCD and the complex factors behind making such a high-risk, high-reward decision. I sought to understand the reasons patients might hesitate in pursuing curative SCD therapies, and to identify the potential impact of clinical nurses and nursing leadership in the decision-making process.

An Aspiring Physician-Scientist Explains How an Award Will Support His Research and His Career

Ayman Mohammad

Ayman Mohammad is a scholarly-year medical student at the Icahn School of Medicine at Mount Sinai in between his third and fourth years of medical school pursuing a Master of Science in  Clinical Research.

Mr. Mohammad recently received an ASH Medical Student Physician-Scientist Award, which provides an opportunity for medical students to gain experience in hematology research under the mentorship of a member of the American Society of Hematology (ASH) and to learn more about the specialty. Awardees agree to spend more than 80 percent of their time during the immersive, yearlong project conducting laboratory, translational, or clinical hematology research. The award provides $42,000 of funding for a one-year period.

At Icahn Mount Sinai, he works in the lab of Bridget Marcellino, MD, PhD, Assistant Professor, Medicine (Hematology and Oncology), investigating the mechanisms behind the pathogenesis of myeloid malignancies. Outside the lab, he co-led Mount Sinai’s Health Policy Program and is now spearheading quality improvement and community-based participatory research efforts at the East Harlem Health Outreach Partnership, Mount Sinai’s student-run free clinic.

In this Q&A, he talks about how the award will support his research, why he chose Icahn Mount Sinai, and his plans for the future.

What research are you conducting related to this award?

My project focuses on understanding the drivers of leukemic transformation and how targeted therapy can halt the progression of hematologic malignancy. Specifically, I will be investigating two negative regulators of the TP53 tumor suppressor pathway, proteins MDM2 and PPM1D. Through targeted protein degradation, we can identify the impact of shutting off these negative regulators on the progression of myeloproliferative neoplasms to acute myeloid leukemia (AML). This project can show  the mechanisms underlying blood cancer pathogenesis and potentially offer a therapeutic solution through protein degrader treatment.

What does the ASH Award mean to you?

I was extremely honored and deeply humbled when I found out that I had received the ASH award. I admire ASH’s commitment to mentorship and supporting the next generation of physician-innovators. Both of my mentors, Dr. Marcellino and Dr. Ronald Hoffman have been recognized by ASH for their work in the hematologic space, so I am grateful to be able to share this opportunity with them and work together on an exciting, novel project this year.

How will this award help your research?

This award will allow me to take time to explore my own research interests during my scholarly year. As a leading organization in hematology-oncology patient care, research, advocacy, and education, ASH represents a future of possibility to me. Their financial support and mentorship offers me a springboard to pursue different career interests. I hope to immerse myself in the world of hematology-oncology and hone my skills as a researcher so that one day I can lead my own investigations with the goal of benefiting patients.

Why did you choose Icahn Mount Sinai and how has the medical school experience been so far?

Growing up in New York, I was always aware of Mount Sinai and its dedication to patients. I was thrilled at the opportunity to train in a community that I had been intimately familiar with growing up and to give back through medicine. Icahn Mount Sinai has been an incredible experience, and every day I am amazed by the work that our faculty, providers, and my fellow classmates are doing. I am excited to produce my own work and help advance our excellent research efforts in understanding heme-malignancy.

What do you hope your impact will be on patients and medical practice?

In my career, I hope to push the boundaries of how we treat heme-malignancies and make medical innovation a central part of my practice. I love translational research because of its potential to transform a scientific discovery in a lab into a disease-modifying therapy for a patient. However, having worked in the sickle cell space before, I understand that sometimes innovation does not reach all patients who need it. I believe that research does not simply end after a publication but rather continues through its impact on patients and practice. As a future physician-innovator, I want to ensure that all patients have equitable access to the fruits of clinical research.

Dermatology Resident Awarded a $1 Million Research Grant to Develop a Comprehensive Molecular Map of Hidradenitis Suppurativa

Kristina Navrazhina, MD, PhD

Kristina Navrazhina, MD, PhD, a first-year dermatology resident at the Icahn School of Medicine at Mount Sinai, has received a $1 million grant for research to provide a comprehensive molecular map of hidradenitis suppurativa (HS)—a skin condition that causes painful lumps deep in the skin—that may define specific subtypes and identify novel therapeutic targets.

Emma Guttman, MD, PhD, the Waldman Professor and Chair of Dermatology and Immunology at the Icahn Mount Sinai, is Co-Principal Investigator on this study.

“Hidradenitis suppurativa is a chronic, debilitating inflammatory skin disease with a highly unmet therapeutic need. There are currently no standardized HS biomarkers, which delays diagnosis and the monitoring of treatment response,” says Dr. Guttman.

Patients present with painful inflamed nodules and abscesses that progress to draining tunnels, commonly affecting places where two skin areas may touch or rub together, such as the armpits or the groin. The disease has an average onset of early adulthood and disproportionately affects underserved communities.

Despite the profound impact on the quality of life, there is still a high unmet need for better treatments. “This grant gives our team the opportunity to discover novel therapeutic options to help bridge this gap,” say Dr. Navrazhina. The grant is from Sanofi, the Paris-based pharmaceutical company.

Molecular mapping may identify early biomarkers of disease progression and capture an earlier window of opportunity for therapeutic intervention. Minimally invasive approaches of tape stripping to collect thin layers of skin and blood serum biomarker analysis will be used to study the molecular profile of HS. The data gathered from this research has the potential to connect clinical practice and therapeutic trials, thereby developing innovative and individualized treatment for HS.

Dr. Navrazhina adds, “We are inspired by our patients to conduct ground-breaking research that can ultimately be used to improve the quality of life for all HS patients.”

“This grant award highlights how the Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai is encouraging and fostering young physician/scientists to become leading scientific investigators of the future,” says Dr. Guttman.

Pin It on Pinterest